Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.57B |
| 2 |
Tesla
TSLA
|
+$1.06B |
| 3 |
Amazon
AMZN
|
+$597M |
| 4 |
Qualcomm
QCOM
|
+$374M |
| 5 |
AbbVie
ABBV
|
+$373M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
+$561M |
| 3 |
UnitedHealth
UNH
|
+$353M |
| 4 |
Meta Platforms (Facebook)
META
|
+$345M |
| 5 |
Starbucks
SBUX
|
+$340M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.63% |
| 2 | Technology | 13.19% |
| 3 | Consumer Discretionary | 10.53% |
| 4 | Financials | 8.74% |
| 5 | Communication Services | 7.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2426
Ingevity
NGVT
$2.62B
| $1.58M | ﹤0.01% |
+18,100
| New | +$1.58M |
|
2427
Fidelity Nasdaq Composite Index ETF
ONEQ
$10.9B
| $1.57M | ﹤0.01% |
45,000
+33,000
| +275% | +$1.1M |
|
2428
Champions Oncology
CSBR
$70.7M
| $1.56M | ﹤0.01% |
187,346
+2,300
| +1% | +$14.2K |
|
2429
Retractable Technologies
RVP
$20.4M
| $1.56M | ﹤0.01% |
1,039,902
+178,660
| +21% | +$231K |
|
2430
iShares US Medical Devices ETF
IHI
$3.46B
| $1.56M | ﹤0.01% |
+35,400
| New | +$1.49M |
|
2431
Aptevo Therapeutics
APVO
$4.49M
| – | – |
0
| – | – |
|
|
AGEN
2432
Agenus
AGEN
$334M
| $1.55M | ﹤0.01% |
19,440
+14,995
| +337% | +$1.01M |
|
2433
Primoris Services
PRIM
$4.49B
| $1.55M | ﹤0.01% |
69,700
-109,617
| -61% | -$2.35M |
|
2434
Rimini Street
RMNI
$469M
| $1.54M | ﹤0.01% |
398,067
+85,718
| +27% | +$343K |
|
|
SVA
2435
DELISTED
Sinovac Biotech, Ltd
SVA
| $1.54M | ﹤0.01% |
2,375,841
| – | – |
|
|
UBP
2436
DELISTED
Urstadt Biddle Properties Inc.
UBP
| $1.54M | ﹤0.01% |
77,300
+5,100
| +7% | +$96.2K |
|
2437
Modine Manufacturing
MOD
$11.1B
| $1.53M | ﹤0.01% |
199,200
-148,409
| -43% | -$1.33M |
|
|
XIN
2438
DELISTED
Xinyuan Real Estate
XIN
| $1.53M | ﹤0.01% |
40,370
+7,482
| +23% | +$295K |
|
|
AC
2439
DELISTED
Associated Capital Group
AC
| $1.52M | ﹤0.01% |
39,095
+4,824
| +14% | +$181K |
|
|
INOV
2440
DELISTED
Inovalon Holdings, Inc. Class A Common Stock
INOV
| $1.52M | ﹤0.01% |
+80,866
| New | +$1.35M |
|
|
FOCS
2441
DELISTED
Focus Financial Partners Inc. Class A
FOCS
| $1.52M | ﹤0.01% |
51,601
-43,999
| -46% | -$1.13M |
|
2442
SITE Centers
SITC
$155M
| $1.52M | ﹤0.01% |
138,942
-262,887
| -65% | -$2.99M |
|
|
STRS
2443
DELISTED
STRATUS PPTYS INC
STRS
| $1.52M | ﹤0.01% |
49,029
+2,529
| +5% | +$72.5K |
|
2444
Dell
DELL
$319B
| $1.52M | ﹤0.01% |
58,259
-1,445,650
| -96% | -$37.6M |
|
|
MFNC
2445
DELISTED
Mackinac Financial Corporation
MFNC
| $1.51M | ﹤0.01% |
86,769
+8,969
| +12% | +$143K |
|
|
FENG
2446
Phoenix New Media
FENG
$18.1M
| $1.51M | ﹤0.01% |
128,282
+7,150
| +6% | +$116K |
|
2447
Protalix BioTherapeutics
PLX
$180M
| $1.51M | ﹤0.01% |
459,634
+14,587
| +3% | +$35.9K |
|
|
WRK
2448
DELISTED
WestRock Company
WRK
| $1.5M | ﹤0.01% |
35,032
-538,630
| -94% | -$21M |
|
2449
AnaptysBio
ANAB
$1.73B
| $1.5M | ﹤0.01% |
+92,400
| New | +$2.19M |
|
2450
S&T Bancorp
STBA
$1.81B
| $1.5M | ﹤0.01% |
37,234
-29,166
| -44% | -$1.1M |
|
Similar funds
Jim Simons's Q4 2019 Portfolio in Review
As of Q4 2019, Jim Simons held 3,913 positions worth $130B, up 10% from $118B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Jim Simons's Q4 2019 filing shows 518 new, 1,836 increased, 1,085 reduced and 443 closed positions. Its largest new stake was Amazon: 6,745,100 shares worth $623M. The largest sale was Celgene Corp, an estimated $1.54B.
By sector, the portfolio is most concentrated in Healthcare at 22% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2019 buy was Amazon: 6,745,100 shares worth $623M.
- Jim Simons added most to Bristol-Myers Squibb in Q4 2019, an estimated $1.57B increase.
- Jim Simons's biggest Q4 2019 reduction was Johnson & Johnson, cutting an estimated $561M.
- Jim Simons fully exited Celgene Corp in Q4 2019, selling an estimated $1.54B.
- Jim Simons's ten largest holdings make up 13% of its $130B portfolio in Q4 2019.
- Jim Simons opened 518 new positions and closed 443 in Q4 2019.
- Jim Simons's portfolio value rose 10% quarter-over-quarter to $130B.
Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.